Anna Irwin, MD
Neurology · Meridian, IDNPI 1407033228
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.7%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 47.8% of the total. Reporting peaked in 2022 at $1,650 and has fallen 81.1% since, to $311 in 2025.
Across 88 payments — averaging $39.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$2K
- Supernus Pharmaceuticals, Inc.$287
- Medtronic$234
- Novartis$190
- Abbott$184
- AbbVie$112
- plus $796 from 22 others
What the payments were for
- Consulting fees$1,65048%
- Speaking & faculty fees$281%
- Food & beverage$1,75051%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 1 | $1,650 |
| Supernus Pharmaceuticals, Inc. | 24 | $287 |
| Medtronic | 2 | $234 |
| Novartis | 11 | $190 |
| Abbott | 1 | $184 |
| AbbVie(2 entities) | 6 | $112 |
| Acadia Pharmaceuticals Inc | 4 | $96 |
| EMD Serono, Inc. | 5 | $84 |
| SK Life Science, Inc. | 2 | $79 |
| Sanofi | 3 | $54 |
| Lilly USA, LLC | 3 | $50 |
| Pfizer | 2 | $50 |
| Greenwich Biosciences, Inc. | 2 | $46 |
| Teva Pharmaceuticals USA, Inc. | 3 | $44 |
| Bristol Myers Squibb | 2 | $33 |
| CSL Behring | 2 | $32 |
| Acorda Therapeutics, Inc | 2 | $28 |
| Genentech USA, Inc. | 2 | $28 |
| Biogen | 2 | $27 |
| Lundbeck LLC | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| AstraZeneca | 1 | $18 |
| Saol Therapeutics Inc. | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Adamas Pharmaceuticals, Inc. | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Neurelis, Inc. | 1 | $14 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XYWAV$1,650
- INTELLIS ADAPTIVESTIM$234
- PROCLAIM$184
How this compares
$3,452 in reported general payments places this provider in the 70th percentile of 59 neurology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Meridian
- Kylie AbeMeridian$16K
- Stephen AsherMeridian$10K
- James HerroldMeridian$6K
- Martha ClineMeridian$3K
- Heidi OrmeMeridian$2K
- Stephen IrelandMeridian$1K
- Jozef OttowiczMeridian$107
- Dax SirucekMeridian$93
- Allen HanMeridian$60
- Bradford TalcottIdaho Falls$252K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.